IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 36 filers reported holding IMPEL NEUROPHARMA INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,020 | -70.4% | 16,325 | -12.4% | 0.01% | -68.8% |
Q2 2023 | $23,680 | -9.3% | 18,646 | 0.0% | 0.02% | -11.1% |
Q1 2023 | $26,104 | -62.7% | 18,646 | 0.0% | 0.02% | -61.7% |
Q4 2022 | $69,923 | -23.2% | 18,646 | 0.0% | 0.05% | -16.1% |
Q3 2022 | $91,000 | -47.7% | 18,646 | 0.0% | 0.06% | -47.7% |
Q2 2022 | $174,000 | +46.2% | 18,646 | 0.0% | 0.11% | +67.2% |
Q1 2022 | $119,000 | -26.1% | 18,646 | 0.0% | 0.06% | -25.6% |
Q4 2021 | $161,000 | – | 18,646 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
5AM Venture Management, LLC | 2,884,791 | $24,896,000 | 4.67% |
venBio Partners LLC | 2,759,791 | $23,817,000 | 4.29% |
Vivo Capital, LLC | 2,884,789 | $24,896,000 | 1.50% |
LASRY MARC | 330,000 | $2,848,000 | 1.41% |
DCF Advisers, LLC | 256,027 | $2,210,000 | 0.90% |
Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $35,693,000 | 0.20% |
EPIQ PARTNERS, LLC | 18,646 | $161,000 | 0.09% |
Anson Funds Management LP | 17,729 | $153,000 | 0.02% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 78,300 | $676,000 | 0.01% |
TRUSTCORE FINANCIAL SERVICES, LLC | 13,407 | $116,000 | 0.01% |